1980 Results
Sort By:
Published on September 5, 2014
Laboratory Corporation of America® Holdings (LabCorp) launched a new business, Enlighten Health Genomics, that builds on the diagnostic potential of next-generation sequencing (NGS) technology. The company said it aims to make genetic profiles a routine part of clinical decisions. Enlighten Health Genomics combines LabCorp’s infrastructure and capabilities with a team…
Published on August 27, 2014
The National Institutes of Health has issued a final NIH Genomic Data Sharing (GDS) policy to promote data sharing as a way to speed the translation of data into knowledge, products, and procedures that improve health while protecting the privacy of research participants. The final policy was posted in the…
Published on August 21, 2014
Illumina formed collaborative partnerships with AstraZeneca, Janssen Biotech, and Sanofi to develop a universal next-generation sequencing (NGS)-based oncology test system. It will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool…
Published on August 13, 2014
Thirteen years after the completion of the Human Genome Project, an increasing number of genomic applications, including next-generation sequencing (NGS), are poised for clinical use. Fulfilling the promise of genomics to improve health in the real world requires a public health perspective. As genomics reaches the bedside, a public health…
Published on August 13, 2014
Next-generation sequencing (NGS) not only continues to make steady advances in the molecular diagnosis of cancers, it also seems to fit perfectly with our current knowledge of the oncogenome. In particular, by making it possible to screen the entire coding sequence of cancer-related genes, NGS overcomes a key problem—cancer predisposition…
Published on August 8, 2014
Advancing the work of The Cancer Genome Atlas (TCGA), a large team of researchers from multiple institutions performed a comprehensive analysis of molecular data from thousands of patients representing 12 different types of cancer. The analysis pointed to an alternative system for classifying cancer. Instead of defining cancers according to…
Published on July 25, 2014
Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds under development that target the SF3B1 gene. Mutations of this gene, which Qiagen said…
Published on July 24, 2014
Cypher Genomics and Illumina have made a pact to co-promote Illumina's sequencing technology, the NextBio platform for data analytics and storage, and Cypher's Coral™ biomarker discovery service to pharmaceutical companies. The firms, through Illumina's sales team, will be promoting the products and service together as part of a solution that,…
Published on July 21, 2014
Berry Genomics chose Illumina's next-generation sequencing technology as the platform on which Berry will aim to secure Chinese Food and Drug Administration (CFDA) regulatory approval for clinical applications. The goal is to expand access to NGS-based tests in China. The companies say have co-developed an NGS system to provide a…
Published on July 17, 2014
A San Diego startup whose technology promises to enable the clinical use of genomics by radically reducing the cost and time of analyzing next-generation sequencing (NGS) data is attractive enough to have drawn Gregory Lucier among investors that have joined to raise $10 million in Series A financing. Lucier has…
Published on July 16, 2014
As you have probably noticed, there’s been a major shift in the focus of next-gen sequencing over the past couple of years. First it was all about new genomes, new techniques, and discovery. Now it’s all about translation. We are entering a new era in next-gen sequencing, one in which…
Published on July 7, 2014
Sequence-based clinical diagnostics firm and deCODE genetics spinout NextCODE Health is partnering with the Academic Centre on Rare Diseases (ACoRD) at University College Dublin, allowing ACoRD to use NextCODE products in research aimed at learning more about the causes and better ways to diagnose autism and rare diseases. NextCODE's Clinical…
Published on June 30, 2014
Illumina entered three separate deals with three European labs under which they will use Illumina's consumables and the HiSeq 2500 to develop and perform noninvasive prenatal testing (NIPT) in their respective nations. French lab-testing service firm Biomnis will make NIPT available in France, Italian molecular genetics lab Genoma will perform…
Published on June 26, 2014
Recent developments reveal both the beginnings of consensus, and many more unresolved issues, when it comes to “incidental” or unexpected findings uncovered during genome or exome sequencing. The American College of Medical Genetics and Genomics (ACMG) retreated in April from its controversial recommendation last year that labs should return incidental…
Published on June 26, 2014
As recently as ten years ago, just after completion of the Human Genome Project, the concept of a personalized approach to cancer treatment was largely just that—an idea of what could be. And companion diagnostics were limited to predicting patient response to Herceptin for breast cancer and Gleevec for chronic…